Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025)

Candel Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 10576000.0 for Q4 2023.

  • On a quarterly basis, Income from Continuing Operations fell 34.3% to 10576000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 38905000.0, a 10.49% decrease, with the full-year FY2025 number at 46470000.0, down 35.19% from a year prior.
  • Income from Continuing Operations hit 10576000.0 in Q4 2023 for Candel Therapeutics, down from 9028000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CADL hit a ceiling of 2525000.0 in Q2 2020 and a floor of 10576000.0 in Q4 2023.
  • Historically, Income from Continuing Operations has averaged 7413600.0 across 4 years, with a median of 8043000.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 197.01% in 2021 and later rose 0.32% in 2023.
  • Tracing CADL's Income from Continuing Operations over 4 years: stood at 6076000.0 in 2020, then fell by 27.57% to 7751000.0 in 2021, then decreased by 1.6% to 7875000.0 in 2022, then crashed by 34.3% to 10576000.0 in 2023.
  • Business Quant data shows Income from Continuing Operations for CADL at 10576000.0 in Q4 2023, 9028000.0 in Q3 2023, and 9770000.0 in Q2 2023.